Literature DB >> 10201481

Increased risk of cancer in ulcerative colitis: a population-based cohort study.

P Karlén1, R Löfberg, O Broström, C E Leijonmarck, G Hellers, P G Persson.   

Abstract

OBJECTIVE: There is an increased risk of colorectal cancer among patients with ulcerative colitis (UC). However, the overall and site specific cancer risks in these patients have been investigated to a limited extent. To study the association between UC and cancer, a population-based study of 1547 patients with UC in Stockholm diagnosed between 1955 and 1984 was carried out.
METHODS: The patients were followed in both the National Cancer Register and the National Cause of Death Register until 1989. For comparisons, regional cancer incidence rates in Stockholm County were used together with individually computed person-years at risk in the UC disease cohort.
RESULTS: A total of 121 malignancies occurred among 97 individuals as compared with 89.8 expected (standardized morbidity ratio [SMR] = 1.4; 95% confidence interval (CI), 1.1-1.6). Overall, an excess number of colorectal cancers (SMR, 4.1; 95% CI, 2.7-5.8), and hepatobiliary cancers in men (SMR = 6.0; 95% CI, 2.8-11.1) associated with primary sclerosing cholangitis, was observed. The risk of pulmonary cancer was decreased (SMR = 0.3; 95% CI, 0.1-0.9). In all, 91 extracolonic malignancies were observed, compared with the 82.3 expected (SMR = 1.11; 95% CI, 0.9-1.3).
CONCLUSIONS: In UC patients, the overall cancer incidence is increased mainly because of an increased incidence of colorectal and hepatobiliary cancer. This increase is partly counterbalanced by a decreased risk of pulmonary cancer compared with that in the general population.

Entities:  

Mesh:

Year:  1999        PMID: 10201481     DOI: 10.1111/j.1572-0241.1999.01012.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  54 in total

Review 1.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

2.  Multiple microcarcinoids in a patient with long standing ulcerative colitis.

Authors:  T Matsumoto; Y Jo; R Mibu; M Hirahashi; T Yao; M Iida
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

3.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

4.  Colitic cancer developed after introduction of azathioprine.

Authors:  Jun-ichi Sasaki; Yutaka J Kawamura; Fumio Konishi; Tsutomu Tosha
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

5.  Risk of lymphoma: inflammatory bowel disease and immunomodulators.

Authors:  Y S Ang; R J Farrell
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 6.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

7.  Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?

Authors:  Akbar K Waljee; Ryan W Stidham; Peter D R Higgins; Sandeep Vijan; Sameer D Saini
Journal:  J Crohns Colitis       Date:  2013-08-12       Impact factor: 9.071

8.  Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.

Authors:  Jeffrey B Brown; Goo Lee; Elizabeth Managlia; Gery R Grimm; Ramanarao Dirisina; Tatiana Goretsky; Paul Cheresh; Nichole R Blatner; Khashayarsha Khazaie; Guang-Yu Yang; Linheng Li; Terrence A Barrett
Journal:  Gastroenterology       Date:  2009-10-29       Impact factor: 22.682

Review 9.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Prevalence of gastrointestinal diseases in two British national birth cohorts.

Authors:  A G C Ehlin; S M Montgomery; A Ekbom; R E Pounder; A J Wakefield
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.